


Idiopathic Pulmonary Fibrosis Treatment Market to Hit USD 7.81 billion by 2034, Sustaining a 6.9 % Annual Growth Rate

The growing prevalence of idiopathic pulmonary fibrosis (IPF) is driving the market demand.

NEW YORK CITY, NY, UNITED STATES, November 11, 2024 /

EINPresswire.com/ -- Our [idiopathic pulmonary fibrosis treatment market](#) report has been prepared using advanced methodologies and research techniques to help businesses make strategic business decisions.

The most recent research study by Polaris Market Research reveals that the idiopathic pulmonary fibrosis treatment market is anticipated to flourish at a stable rate. With a projected CAGR of 6.9%, the market was valued at USD 4.01 billion in 2024. It is ready to grow to USD 7.81 billion by 2034.



□□□□□□ □□□□□□□□□□□□□□:

Idiopathic pulmonary fibrosis is a lung illness that takes place when lung tissue becomes injured and blemished. This dense, inflexible tissue renders it difficult for the lungs to function appropriately. The doctor or the healthcare expert evaluates the medical and family history and does a physical exam. He also questions if the patient has come in contact with dust, gases, and chemicals, particularly through work.

Tests such as chest X-rays may exhibit the blemished tissue that is normally a constituent of pulmonary fibrosis. Often, the chest x-ray may not portray any alterations. Additional tests may be required to detect why one is short of breath. As more patients are detected with idiopathic pulmonary fibrosis, it pushes the idiopathic pulmonary fibrosis treatment market demand.

□□□□□□□□ □□□□ □□□□□□ □□ □□□□ □□ □□□ □□□□□□:



The disfiguring of lung tissue causes strain on breathing and reduces oxygen supply."

Polaris Market Research

<https://www.polarismarketresearch.com/industry-analysis/idiopathic-pulmonary-fibrosis-treatment-market/request-for-sample>

□□□□□□ □□□□□□□□ □□□ □□□□□□□□□□□□□□:

Growing Smoking Rates: The market is growing due to altering lifestyle routines, especially growing smoking rates

and susceptibility to environmental contaminants. Perilous bearing, such as smoking tobacco and utilizing enjoyable drugs, together with vocational susceptibility to detrimental materials such as asbestos and industrial chemicals, boosts the demand for idiopathic pulmonary fibrosis treatment market growth.

Rise in Geriatric Population: Senior persons are more vulnerable to pulmonary fibrosis because of age-connected deprivation of preservative stem cells and pericytes, which can cause fibroblast stimulation and spread. As the worldwide population matures, the cases of idiopathic pulmonary fibrosis rise.

Advancement in Diagnostic Procedures: Progression in diagnostic procedures is notably driving the market. Enhanced imaging strategies such as high-resolution computed tomography (HRCT) sanction premature and more precise perception of IPF, easing punctual mediation.

□□□ □□□□□□□□□□ □□ □□□□□□□□□□ □□□□□□□□□ □□□□□□□□ □□□□□□□□ □□□□□□:

- F. Hoffmann-La Roche Ltd
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Medicinova, Inc
- Merck & Co., Inc.
- Galapagos NV
- Novartis AG
- Fibrogen, Inc.
- Avalyn Pharma Inc.
- Promedior, Inc.

□□□□□□□□ □□□ □ □□□□□□□□□ □□ □□□□□ □□□□□□ □□□□□□□□□□:

<https://www.polarismarketresearch.com/industry-analysis/idiopathic-pulmonary-fibrosis-treatment-market/request-for-discount-pricing>

□□□□□□□□□□ □□□□□□□□□□:

- The idiopathic pulmonary fibrosis treatment market segmentation is based on drug class, route of administration, distribution channel, and region.

- By route of administration analysis, the oral segment held the largest market share. This is due to its convenience, enhanced patient conformity, and the possibility of outpatient handling.
- By distribution channel analysis, the hospital pharmacies segment is poised to register a significant CAGR. This is due to the surge in specific treatment agreements customized for IPF patients.

Research Report Scope:

The research report covers all the major regions and sub-regions of the idiopathic pulmonary fibrosis treatment market. The study provides market insights into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America: North America accounted for the largest market share. This is primarily because of the progressive medical framework. As per the American Hospital Association and the Government of Canada, the region possesses 6742 hospitals and provides specific care and inventive therapies.

Asia Pacific: Asia Pacific is anticipated to witness the fastest CAGR from 2024 to 2032. The region's productive treatment alternatives and healthcare framework fuel the regional market expansion.

For more information, visit:

<https://www.polarismarketresearch.com/industry-analysis/idiopathic-pulmonary-fibrosis-treatment-market/inquire-before-buying>

FAQs:

How much is the idiopathic pulmonary fibrosis treatment market?

The market size was valued at USD 4.01 billion in 2024 and is projected to grow to USD 7.81 billion by 2034.

What is the growth rate of the idiopathic pulmonary fibrosis treatment market?

The global market is projected to register a CAGR of 6.9% during the forecast period.

Which region held the largest market share?

North America accounted for the largest share of the global market in 2024.

Which segment by route of administration would register a significant CAGR in the market during the forecast period?

The oral segment is anticipated to record a significant CAGR in the global market during the forecast period.

□□□□□□ □□□□ □□□□□□□□ □□□□□□□□:

Digital X-Ray Market

<https://www.polarismarketresearch.com/industry-analysis/digital-x-ray-market>

Drug Device Combination Products Market

<https://www.polarismarketresearch.com/industry-analysis/drug-device-combination-products-market>

Lifestyle Diseases Apps Market

<https://www.polarismarketresearch.com/industry-analysis/lifestyle-diseases-apps-market>

Disposable Endoscopes Market

<https://www.polarismarketresearch.com/industry-analysis/disposable-endoscopes-market>

Medical Telepresence Robots Market

<https://www.polarismarketresearch.com/industry-analysis/medical-telepresence-robots-market>

□□□□□ □□□□□□□□ □□□□□□ □□□□□□□□ & □□□□□□□□□□□, □□□:

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

Likhil G

Polaris Market Research and Consulting

+ + +1 929-297-9727

sales@polarismarketresearch.com

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/759582322>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.